Key Highlights

● Shares closed at $11.99 at their last session, down 2.44% on the day.

● Cellebrite reported second-quarter 2026 Revenue of about $131.1 million, up about 16% year over year, with ARR of about $507.8 million, up about 21%.

● The company lowered its full-year 2026 ARR and revenue guidance, citing longer sales cycles and slower Inseyets platform conversions.

● Cellebrite raised its adjusted-EBITDA target to about $153 million to $159 million despite the reduced growth outlook.

Cellebrite (NASDAQ:CLBT) shares closed at $11.99 at their last session, down 2.44% on the day, after the provider of digital-intelligence software used by law enforcement and enterprises lowered its full-year revenue and ARR guidance. For investors, the breakout framing that once surrounded the stock must now be weighed against a guidance cut that pressured shares.

Cellebrite sells software and services that help investigators lawfully access, collect and analyze digital evidence from smartphones and other sources, generating largely recurring subscription revenue measured by annual Recurring Revenue (ARR).

Latest Developments

In its second-quarter 2026 results, Cellebrite reported revenue of about $131.1 million, up about 16% year over year, with a gross Margin around 80.8%, and ARR of about $507.8 million, up about 21%. However, the company lowered its full-year 2026 guidance, reducing its ARR outlook to about $550 million to $560 million and revenue to about $555 million to $561 million, while raising its adjusted-EBITDA target to about $153 million to $159 million.

Management attributed the reduced growth outlook to longer sales cycles and slower-than-expected expansion from conversions to its Inseyets platform, describing a more measured view of new-product contributions.

Financial and Business Position

Cellebrite's recurring-revenue model, high gross margins and continued ARR growth reflect a differentiated position in digital-intelligence software with a largely public-sector customer base. However, the lowered ARR and revenue guidance, driven by longer sales cycles and slower Inseyets conversions, is the key concern, indicating that growth is decelerating even as the company raised its profitability target.

Stock-Market Context

Shares closed at $11.99 at their last session, down 2.44% on the day. The stock carries a strong-buy rating, but the reduced revenue and ARR guidance weighed on sentiment despite the raised EBITDA target. Any breakout case would rest on sales cycles normalizing, Inseyets conversions accelerating, and ARR growth reaccelerating. The cautionary case is the lowered guidance and the deceleration in growth.

Better Margins Today Against a Softer Growth Path

Cellebrite's quarter is a study in how a fundamentally healthy software business can still disappoint the market when growth expectations reset. The underlying Franchise is genuinely strong: digital-intelligence software for lawfully accessing and analyzing device data is mission-critical for law enforcement and enterprises, it commands gross margins above 80%, and its recurring revenue grew ARR past $500 million.

The problem is direction of travel: management lowered its full-year ARR and revenue guidance, citing longer sales cycles and slower-than-hoped conversions to its newer Inseyets platform, meaning the growth rate is decelerating even as profitability improves, which is why the company simultaneously raised its EBITDA target. That combination is precisely the kind of mixed signal investors must weigh honestly: better margins today against a softer growth trajectory tomorrow.

Investors watching this story will want to see whether the elongated sales cycles prove temporary and Inseyets conversions reaccelerate ARR growth. For investors, the decisive question is whether the guidance cut marks the start of a more durable slowdown or a temporary pause in a business that still enjoys strong margins and an entrenched customer base.